There is innovation in the Mexican pharmaceutical industry! Although there is a belief that little to no innovation takes place in Mexico, researchers in universities and companies alike have demonstrated that the past statement is far from the truth. Mexico is the 12th pharmaceutical market worldwide and 2nd in Latin America.
The company Caramel Tech, has developed two of the most innovative technologies in Mexico, which are top leading technologies worldwide. One of which is "Modified polyhedrin, polyhedras and biotech products derived from them" This technology consist of a platform that uses baculovirus expression system for insect cells (BEVS) to encapsulate recombinant proteins and enzymes to generate highly stable biotechnological products. BEVS is a novel procedure used to make stable proteins that can be used in vaccines by taking advantage of the polyhedrin production system in insect cultures to manufacture effective recombinant proteins. This process requires the fusion of a recombinant sequence with a polyhedrin sequence which is then inserted into a BEVS factor, resulting in production of high amounts of encapsulated proteins that are resistant to heat and dehydration. These characteristics make it an advantageous procedure because when used in vaccine production, these proteins do not have to be transported in a "cold chain" which reduces delivery costs and increases immunization efficiency. BEVS increases thermal stability, shelf duration, production, and purification rates of vaccines which makes it an ideal system for the vaccine production.
Their second project, "NTS-Poyplex: A potential Nanocarrier for Neurotrophic Therapy of Parkinson's disease", is a therapy uses a synthetic nanocarrier, NTS-Polyplex, to deliver genes to the dopamine neurons in the brain in order to reverse the damage from Parkinson's disease. The NTS-Polyplex is bound with plasmid DNA and endocytosed into the dopamine neurons. Once inside the neuron, it can be incorporated into the DNA of the actual neuron, correcting nerve damage caused by PD. NTS-Polyplex therapy avoids further neuron degeneration like current treatments do. This is a very promising gene therapy for people with Parkinson's disease and although it remains yet to be tested in human subjects, there is potential for its approval as gene therapy.
Join us in Biopharma Mexico this October and understand first-hand how Mexico's researchers are innovating to take Mexico into the forefront of the pharmaceutical industry.